myWHRO SIGN IN
Dr. Paul Marik a pulmonary and critical care specialist.
Healing or harming? That's the question Dr. Paul Marik faced as the pandemic spread through the country. He soon found his methods of treatment for COVID-19 were at odds with leaders in the hospital where he practiced.
Marik is a pulmonary and critical care specialist who currently serves as chairman and chief scientific officer of the Frontline COVID-19 Critical Care Alliance (FLCCC Alliance). He was previously a professor of medicine and chief of pulmonary and critical care medicine at Eastern Virginia Medical School (EVMS).
He resigned from EVMS in 2021 amid controversy over his use of ivermectin and other COVID-19 treatments in caring for patients. Marik maintains that drugs like Ivermectin, an anti-parasite medicine for which its creators won a Nobel Prize, is a safe and effective way to treat patients in the early stages of COVID-19—at a cost that is significantly lower than other drugs currently being used.
In this interview with Watching America’s host Dr. Alan Campbell, Marik explains his use of Ivermectin and the larger implications to the healthcare system that he believes come from prohibiting doctors from determining the best course of treatment for their patients. He also discusses the influence that pharmaceutical companies have on healthcare and on medical research, the fallout he has experienced while trying to “do no harm," and what he is working on now.
Though he has been maligned by some physicians in the media and online, in March, the Virginia House of Delegates passed a resolution commending Marik’s work during the pandemic.
Busy when the show airs? You can always find episodes archived online.
